These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 20504223

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

  • 6. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 8. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.
    Cancer; 2012 May 01; 118(9):2525-31. PubMed ID: 22028294
    [Abstract] [Full Text] [Related]

  • 9. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS.
    Cancer Res Treat; 2017 Jul 01; 49(3):678-687. PubMed ID: 27737534
    [Abstract] [Full Text] [Related]

  • 10. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R, Taron M, Alberola V, Massuti B, Felip E.
    Lung Cancer; 2003 Aug 01; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [Abstract] [Full Text] [Related]

  • 11. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P.
    Ann Oncol; 2004 Aug 01; 15(8):1194-203. PubMed ID: 15277258
    [Abstract] [Full Text] [Related]

  • 12. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q.
    J Cancer Res Clin Oncol; 2013 Jan 01; 139(1):25-38. PubMed ID: 22864816
    [Abstract] [Full Text] [Related]

  • 13. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.
    Ann Oncol; 2006 Dec 01; 17(12):1818-25. PubMed ID: 16980606
    [Abstract] [Full Text] [Related]

  • 14. Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy?
    Polat G, Yılmaz U, Anar C, Kömürcüoğlu B, Aydoğdu Z.
    Indian J Cancer; 2015 Dec 01; 52(3):277-80. PubMed ID: 26905109
    [Abstract] [Full Text] [Related]

  • 15. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
    Zhang L, Liu T, Zhang JQ.
    Zhonghua Zhong Liu Za Zhi; 2011 Mar 01; 33(3):212-6. PubMed ID: 21575522
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R.
    Clin Cancer Res; 2002 Jul 01; 8(7):2286-91. PubMed ID: 12114432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
    Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.
    J Clin Oncol; 2013 Jul 01; 31(19):2404-12. PubMed ID: 23690416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.